Drug intelligence / Profile preview

lidocaine + pregabalin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Topical, Oral

Overview

A combination therapy consisting of lidocaine (typically as a 5% patch) and pregabalin (oral medication). This combination targets neuropathic pain through complementary mechanisms - lidocaine acts as a local anesthetic that numbs nerves topically, while pregabalin works in the central nervous system to decrease pain signals from damaged nerves. The combination is particularly effective for patients with neuropathic pain conditions who have not achieved adequate relief with monotherapy.

Targets

CACNA2D2 (α2δ-2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine + pregabalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + pregabalin.

Explore the full profile